Last reviewed · How we verify
HUTCHMED (China) — Portfolio Competitive Intelligence Brief
HCM (NASDAQ)
0 marketed
0 filed
2 Phase 3
2 Phase 2
7 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| R-GemOx | R-GemOx | phase 3 | chemotherapy | Oncology | ||
| HMPL-760 | HMPL-760 | phase 3 | FGFR inhibitor | FGFR (Fibroblast Growth Factor Receptor) | Oncology |
Therapeutic area mix
- Oncology · 3
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Assistance Publique - Hôpitaux de Paris · 1 shared drug class
- Bayer · 1 shared drug class
- Beta Pharma Shanghai · 1 shared drug class
- Betta Pharmaceuticals Co., Ltd. · 1 shared drug class
- Caliway Biopharmaceuticals Co., Ltd. · 1 shared drug class
- Chengdu New Radiomedicine Technology Co. LTD. · 1 shared drug class
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 shared drug class
- Allist Pharmaceuticals, Inc. · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for HUTCHMED (China):
- HUTCHMED (China) pipeline updates — RSS
- HUTCHMED (China) pipeline updates — Atom
- HUTCHMED (China) pipeline updates — JSON
Cite this brief
Drug Landscape (2026). HUTCHMED (China) — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/hutchmed. Accessed 2026-06-10.